Skip to main content
Equibles
RLMD logo

RLMD · Relmada Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track RLMD — free

Use RLMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RLMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.77 +0.04 (+1.07%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$408.55M
Shares
106.67M
Volume · Sep 30 999.53K Avg daily vol (3M) 1.36M

Relmada Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Relmada Therapeutics, Inc. (RLMD), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Earnings call
FY26 · Q2
2026-08-06
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call
Diluted EPS
$-0.11
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Relmada Therapeutics, Inc. (RLMD) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Confident tone Intellectual property Phase 3 registrational program NDV01 Phase 2 efficacy data
Diluted EPS
$-0.22
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Confident tone Phase III RESCUE program NDV-01 clinical data and efficacy Regulatory and FDA considerations
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Confident tone NDV-01 phase two data NMIBC market opportunity BCG-naive BRIDGE study / off-label potential
Diluted EPS
$-0.30
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Confident tone NDV-01 Phase II 6-month data Sepranolone and Prader-Willi syndrome Pipeline advancement and upcoming trials
Diluted EPS
$-0.30
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript
Confident tone NDV-01 for non-muscle invasive bladder cancer Sepranolone for CNS indications Competitive landscape in NMIBC
Diluted EPS
$-0.58
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript
Positive tone REL-1017 Phase 3 program Reliance II interim analysis Futility and clinical significance threshold
Diluted EPS
$-0.72
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript
Positive tone REL-1017 Phase 3 Program (Reliance II & Relight) Preplanned Interim Analysis REL-P11 Psilocybin Program for Metabolic Disease
Diluted EPS
$-0.59
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Call Transcript
Positive tone Phase III REL-1017 program execution Psilocybin modified-release program Site management and trial oversight
Diluted EPS
$-0.72
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript
Positive tone RELIGHT (Study 304) Phase 3 progress REL-1017 / RELIANCE II enrollment and protocol changes Modified-release psilocybin preclinical/Phase 1 program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.73
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Relmada Therapeutics, Inc. (RLMD) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.84
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Relmada Therapeutics, Inc. (RLMD) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.87
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Relmada Therapeutics, Inc. (RLMD) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Relmada Therapeutics, Inc. (RLMD) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.31
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Relmada Therapeutics, Inc. (RLMD) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.33
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Relmada Therapeutics, Inc. (RLMD) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-23
Relmada Therapeutics, Inc. (RLMD) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Relmada Therapeutics, Inc. (RLMD) Q3 2021 Earnings Call Transcript
Diluted EPS
$-2.44
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Relmada Therapeutics, Inc. (RLMD) Q2 2021 Earnings Call Transcript
Diluted EPS
$-1.56
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Relmada Therapeutics, Inc. (RLMD) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-23
Relmada Therapeutics, Inc. (RLMD) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 1553643 CUSIP 75955J402 13F (30d) 3 filings 3 filers Visit website Investor relations